As of April 17, 2026, Cue Biopharma's top three insider holders are Aaron G.L. Fletcher (Director, 940.00K shares), Cameron Gray (Director, 687.05K shares), Cameron Gray (Director, 687.05K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Aaron G.L. Fletcher | - | 0 | 940,000 | 25 May, 2022 |
| Cameron Gray | - | 687,049 | 0 | 16 Jun, 2022 |
| Cameron Gray | - | 687,049 | 0 | 16 Jun, 2022 |
| Pasha Sarraf | - | 323,857 | 0 | 02 Jan, 2026 |
| Pasha Sarraf | - | 323,857 | 0 | 02 Jan, 2026 |
| Daniel R Passeri | Chief Executive Officer | 164,578 | 0 | 18 Dec, 2024 |
| Daniel R Passeri | Chief Executive Officer | 164,578 | 0 | 18 Dec, 2024 |
| Anish Suri | President And Cso | 135,638 | 0 | 29 Aug, 2023 |
| Anish Suri | President And Cso | 135,638 | 0 | 29 Aug, 2023 |
| Frank Morich | - | 28,000 | 0 | 31 May, 2022 |
| Kerri-Ann Millar | Chief Financial Officer | 14,311 | 0 | 23 Aug, 2022 |
| Kerri-Ann Millar | Chief Financial Officer | 14,311 | 0 | 23 Aug, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Apr, 2026 | Lucinda Warren | Stock Option (right to buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 09 Apr, 2026 | Daniel G. Baker | Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 09 Apr, 2026 | Colin Sandercock | Stock Option (right to buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 02 Jan, 2026 | Pamela Garzone | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Jill Marie Broadfoot | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Peter A Kiener | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pasha Sarraf | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Patrick Verheyen | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 4,229 | $0.31 | 4,229 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 77,148 | $0.30 | 81,377 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 86,947 | $0.32 | 168,324 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 78,116 | $0.31 | 246,440 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 77,417 | $0.30 | 323,857 | D | P |
| 26 Sep, 2025 | Colin Sandercock | Stock Option (right to buy) | A | 30,000 | $0.00 | 30,000 | D | A |
| 03 Dec, 2025 | Colin Sandercock | Stock Option (right to buy) | A | 70,000 | $0.00 | 70,000 | D | A |
| 29 Sep, 2025 | Lucinda Warren | Stock Option (right to buy) | A | 125,000 | $0.00 | 125,000 | D | A |
| 29 Sep, 2025 | Daniel G. Baker | Stock Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 29 Sep, 2025 | Usman Azam | Stock Option (right to buy) | A | 1,875,000 | $0.00 | 1,875,000 | D | A |
| 04 Jun, 2025 | Jill Marie Broadfoot | Stock Option (right to buy) | A | 48,800 | $0.00 | 48,800 | D | A |
| 21 Mar, 2025 | Lucinda Warren | Stock Option (right to buy) | A | 250,000 | $0.00 | 250,000 | D | A |